Ask AI
ProCE Banner Series

From Today to Tomorrow: Iberdomide’s New Approval in Multiple Myeloma and What It Means for Practice

This educational program will review the mechanistic rationale and clinical evidence supporting the newly approved CELMoD iberdomide in multiple myeloma. Expert faculty will examine key efficacy and safety data, the implications of the new approval for the evolving treatment landscape, and considerations for incorporating iberdomide into clinical practice, including patient selection and treatment sequencing.

Key Takeaways

  • Review unmet needs and the evolving treatment landscape in relapsed/refractory multiple myeloma, including the rationale for targeted protein degradation with CELMoD agents
  • Evaluate the mechanism of action and key efficacy and safety data supporting the newly approved CELMoD iberdomide in multiple myeloma
  • Apply evidence-based strategies for patient selection, treatment sequencing, and integration of iberdomide into clinical practice

All Events

From Today to Tomorrow: Iberdomide’s New Approval in Multiple Myeloma and What It Means for Practice

Upcoming Events

September

10

2026

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual